<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14D-1/A
TENDER OFFER STATEMENT
PURSUANT TO SECTION 14(D)(1) OF THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
(FINAL AMENDMENT)
AND
SCHEDULE 13D/A
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)
ENDOGEN, INC.
(Name of Subject Company)
EWOK ACQUISITION CORP.
PERBIO SCIENCE AB
PERSTORP AB
(Bidders)
COMMON STOCK, PAR VALUE $0.01
(Title of Class of Securities)
29264J 10 8
(Cusip Number of Class of Securities)
MAGNUS LINDQUIST
CHIEF FINANCIAL OFFICER
PERSTORP AB
SE-284 80 PERSTORP, SWEDEN
011-46-435-380-00
COPIES TO:
PATRICIA KAVEE MELICK, ESQ.
WIGGIN & DANA
THREE STAMFORD PLAZA
STAMFORD, CONNECTICUT 06911
(203) 363-7600
(Name, Address and Telephone Number of Persons Authorized to Receive Notices
and Communications on Behalf of Bidders)
July 7, 1999
(Date of Event which Requires Filing Statement on Schedule 13D)
<PAGE>
<TABLE>
<S> <C> <C> <C>
- -----------------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Ewok Acquisition Corp.
- -----------------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [__]
- -----------------------------------------------------------------------------------------
3. SEC USE ONLY
- -----------------------------------------------------------------------------------------
4. SOURCE OF FUNDS*
AF
- -----------------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f) [__]
- -----------------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts
- -----------------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 0
SHARES --------------------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 3,468,202
OWNED BY --------------------------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER 0
REPORTING --------------------------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER 3,468,202
- -----------------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,468,202
- -----------------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [__]
- -----------------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
100%
- -----------------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
- -----------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C>
- -----------------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
PerBio Science AB
- -----------------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [__]
- -----------------------------------------------------------------------------------------
3. SEC USE ONLY
- -----------------------------------------------------------------------------------------
4. SOURCE OF FUNDS*
AF
- -----------------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f) [__]
- -----------------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Sweden
- -----------------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 0
SHARES --------------------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 3,468,202
OWNED BY --------------------------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER 0
REPORTING --------------------------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER 3,468,202
- -----------------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,468,202
- -----------------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [__]
- -----------------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
100%
- -----------------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
- -----------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE>
<TABLE>
<S> <C> <C> <C>
- -----------------------------------------------------------------------------------------
1. NAMES OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Perstorp AB
- -----------------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [X]
(b) [__]
- -----------------------------------------------------------------------------------------
3. SEC USE ONLY
- -----------------------------------------------------------------------------------------
4. SOURCE OF FUNDS*
WC
- -----------------------------------------------------------------------------------------
5. CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEM 2(e) or 2(f) [__]
- -----------------------------------------------------------------------------------------
6. CITIZENSHIP OR PLACE OF ORGANIZATION
Sweden
- -----------------------------------------------------------------------------------------
NUMBER OF 7. SOLE VOTING POWER 0
SHARES -------------------------------------------------------------------
BENEFICIALLY 8. SHARED VOTING POWER 3,468,202
OWNED BY -------------------------------------------------------------------
EACH 9. SOLE DISPOSITIVE POWER 0
REPORTING -------------------------------------------------------------------
PERSON WITH 10. SHARED DISPOSITIVE POWER 3,468,202
- -----------------------------------------------------------------------------------------
11. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
3,468,202
- -----------------------------------------------------------------------------------------
12. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* [__]
- -----------------------------------------------------------------------------------------
13. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
100%
- -----------------------------------------------------------------------------------------
14. TYPE OF REPORTING PERSON*
CO
- -----------------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
</TABLE>
<PAGE>
EXPLANATORY NOTE
This Amendment No. 3 to Tender Offer Statement on Schedule 14D-1/A and
Amendment No. 3 to Schedule 13D on Schedule 13D/A (collectively, along with the
original Schedule 14D-1 and Schedule 13D and Amendment Nos. 1 and 2 to the
original Schedule 14D-1 and Schedule 13D, the "Schedule 14D-1") relates to the
offer by Ewok Acquisition Corp., a Massachusetts corporation ("Purchaser") and a
wholly-owned subsidiary of PerBio Science AB, a Swedish corporation ("Parent"),
which is a direct wholly-owned subsidiary of Perstorp AB, a Swedish corporation,
to purchase all outstanding shares of common stock, $.01 par value per share
(the "Shares"), of Endogen, Inc., a Massachusetts corporation (the "Company"),
at a price of $3.75 per Share, net to the seller in cash, upon the terms and
subject to the conditions set forth in the Purchaser's Offer to Purchase, dated
June 2, 1999 (the "Offer to Purchase"), as supplemented by the Supplement to
Offer to Purchase, dated June 17, 1999 (the "Supplement"), and the related
Letter of Transmittal, copies of which have been attached to the Schedule 14D-1
as Exhibits (a)(1), (a)(10) and (a)(2), respectively.
Capitalized terms used, but not otherwise defined, herein have the
meanings ascribed to such terms in the Offer to Purchase, as amended by the
Supplement.
ITEM 6. INTEREST IN SECURITIES OF THE SUBJECT COMPANY.
Items 6(a) and 6(b) of the Schedule 14D-1 are hereby amended and
supplemented by the following:
The Offer terminated at 12:00 midnight, New York City Time, on
Wednesday, July 7, 1999. On July 8, 1999, Parent accepted 3,171,794 Shares for
payment, which constituted 91.45% of the outstanding Shares. After accepting
such Shares for payment, Purchaser filed Articles of Merger with the Secretary
of Commonwealth of the Commonwealth of Massachusetts and thereby effected a
short form merger of the Company with and into Purchaser. See Item 10(f)
below.
On July 8, 1999, Purchaser issued a press release announcing the
successful completion of the Offer. A copy of the press release is attached
hereto as Exhibit (a)(13) and is incorporated herein by this reference.
ITEM 10. ADDITIONAL INFORMATION.
Item 10(f) of the Schedule 14D-1 is hereby amended and supplemented by
the following:
On July 8, 1999, after accepting the Shares for payment, Purchaser filed
Articles of Merger with the Secretary of Commonwealth of the Commonwealth of
Massachusetts effecting the statutory short form merger of the Company with and
into Purchaser in accordance with Massachusetts law. Concurrent with such
filing, Purchaser filed Articles of Amendment changing the name of Purchaser to
Endogen, Inc. In the merger, shares not owned by Purchaser were converted into
the right to receive $3.75 per Share in cash, subject to appraisal rights.
ITEM 11. MATERIAL TO BE FILED AS EXHIBITS.
(a)(15) Press Release of Parent, dated July 8, 1999.
<PAGE>
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify
that the information set forth in this statement is true, complete and correct.
Dated: July 12, 1999
EWOK ACQUISITION CORP.
By: /s/ Robb Anderson
_________________________________
Name: Robb Anderson
Title: President
PERBIO SCIENCE AB
By: /s/ Mats Fischier
_________________________________
Name: Mats Fischier
Title: Director
PERSTORP AB
By: /s/ Ake Fredriksson
_________________________________
Name: Ake Fredriksson
Title: President and Chief Executive Officer
<PAGE>
EXHIBIT INDEX
(a)(13) Press Release of Parent, dated July 8, 1999.
<PAGE>
PRESS RELEASE
Perstorp AB Acquires Endogen, Inc.
ROCKFORD, Ill., July 8 -- Perstorp AB subsidiary PerBio Science AB
today announded that it has completed its merger with Endogen, Inc.
The merger follows a successful cash tender offer for the outstanding
shares of Endogen. Any shares not acquired in the tender offer will be exchanged
for $3.75 per share in cash, the tender offer price. Stockholders of Endogen who
did not tender their shares should anticipate receiving transmittal material
shortly detailing instructions for transmitting their shares in exchange for the
merger consideration.
PerBio Science AB, which is a leading supplier in several life science
product segments, consists of the American companies Pierce Chemical Company of
Rockford, Ill., and HyClone Laboratories, Inc. of Logan, Utah, and of the
Sweden-based company Atos Medical. As part of PerBio Science AB, Endogen, Inc.
will be closely affiliated with Pierce Chemical Company.
Mr. Robb Anderson, President of Pierce Chemical company, said today,
"The merger of Endogen, Inc. will strengthen PerBio Science's position as a
world leader providing biotechnology products for the rapidly growing life
science research and drug discovery markets. Endogen's product portfolio adds to
our existing product lines and will enable PerBio Science to expand its
offerings of high-tech products for immunologists, molecular biologists and cell
biologists."
Pierce Chemical Company, an ISO 9001 certified company, is an
internationally recognized leader in the development and supply of quality,
innovative life science and analytical research products with facilities located
in Rockford and Milwaukee.
Endogen, Inc. is a supplier of specialty reagents, immunoassay test kits
and molecular research products to customers involved in biomedical research,
the biotechnology industry and pharmaceutical drug discovery, with facilities
located in Woburn, Mass.
"We are exicited about the opportunities presented to Endogen by this
merger with PerBio Science," stated Mr. Owen Dempsey, President of Endogen.
"Working closely with Pierce Chemical Company, we expect to leverage our
activities worldwide, in order to benefit Endogen customers through expanded
product development, market penetration and customer service."
PerBio Science AB, the former Perstorp Life Science Division, is a
wholly owned subsidiary of Perstorp AB, a global chemistry and materials
technology corporation located in Perstorp, Sweden. In October 1999, PerBio
Science AB is to be spun off to shareholders and listed on the Stockholm Stock
Exchange.
SOURCE Perstorp AB
